Meningiomas are slow growing, extraaxial tumors that derive from the arachnoidal cap cells of the meninges. Resection remains the main modality of treatment and can be curative in some cases. External-beam radiotherapy and radiosurgery can benefit selected patients. The role of chemotherapy continues to be defined, but should be considered for patients with inoperable or frequently recurring me...

Cells of a transplantable murine lymphoma line were partially synchronized in vivo by administration of a single dose of 0.5 mg of hydroxyurea per lymphoma-bearing mouse. At various times after administration of hydroxyurea, the femurs of the lymphomatous mice were X-irradiated, and the number of lymphoma colony-forming units per femur were then assayed by the spleencolony technique. A well-def...

Carbamoyloxyurea, an oxidation product of hydroxyurea, is bactericidal for Escherichia coli. Drug-induced killing is independent of cellular metabolism; ribonucleic acid and protein syntheses are the processes most affected, and the lethal action is accompanied by degradation of cellular deoxyribonucleic acid. In all of these effects the drug differs from hydroxyurea, a primarily bacteriostatic...

Fetal hemoglobin (Hb F) may increase in patients receiving chemotherapeutic drugs, a result of potential use in patients with symptomatic hemoglobinopathies. We examined Hb F in 13 patients with myeloproliferative disease (six polycythemia vera, five polycythemia vera with myeloid metaplasia, one agnogenic myeloid metaplasia, and one chronic myelogenous leukemia) who were treated with hydroxyur...

The nature of the inhibition of Ehrlich tumor cell ribonucleotide reductase by combinations of agents directed at the non-heme iron-containing component and the effector-binding component was studied with the use of isobolograms. From these studies, it was determined that the combinations of pyrazoloimidazole (IMPY) and dialdehyde of inosine, IMPY and deoxyguanosine triphosphate (dGTP), IMPY an...

Hydroxyurea is the only FDA approved treatment of sickle cell disease. It is believed that the primary mechanism of action is associated with the pharmacological elevation of nitric oxide in the blood; however, the exact details of this are still unclear. In the current work, we investigate the atomic level details of this process using a combination of flexible-ligand/flexible-receptor virtual...

Sickle cell disease (SCD) is an inherited disorder in which sickled red blood cells occlude the small vessels of the body, reducing oxygen delivery to tissues and ultimately negatively affecting many of the body's major organs. Hydroxyurea has proven beneficial in the treatment of SCD and prevention of disease-related complications. The 2014 guidelines put forth by the National Heart, Lung, and...

INTRODUCTION Administration of hydroxyurea in sickle cell disease is associated with a dramatic increase of HbF along with a significant clinical improvement and, occasionally, increased total hemoglobin levels. The underlying mechanisms are not yet fully elucidated. MATERIALS AND METHODS We report the response of three patients with homozygous sickle cell disease and 10 patients with compoun...

BACKGROUND The development of painful leg ulcers in the ankle area is a rare and only partially described complication in patients receiving high-dose, long-term hydroxyurea treatment for myeloproliferative diseases. Several reports have described treatments for chronic wound management with this type of lesion. OBSERVATIONS We describe 2 patients who were diagnosed as having hydroxyurea-indu...

The nature of the inhibition of Ehrlich tumor cell ribonucleotide reducÃ-ase by combinations of agents directed at the nonheme iron-containing component and the effector-binding com ponent was studied with the use of isobolograms. From these studies, it was determined that the combinations of pyrazoloimidazole (IMPY) and dialdehyde of inosine, IMPY and deoxyguanosine triphosphate (dGTP), IMPY a...